
Entrada Therapeutics, Inc. (TRDA) Stock Ticker
TRDA right now
Market factors today
Unlock the full TRDA picture
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
TRDA stock facts
| Ticker symbol | TRDA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $239.1M |
| CEO | Dipal Doshi |
| Employees | 152 |
| Headquarters | Boston, MA, US |
| IPO date | 2021-10-29 |
| Website | www.entradatx.com |
What you can see for TRDA on Tickr
Live TRDA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TRDA report.
Rankings
FAQ
What is the ticker symbol for Entrada Therapeutics, Inc.?
The ticker symbol for Entrada Therapeutics, Inc. is TRDA, listed on the NASDAQ Global Market.
What is TRDA?
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product…